Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VIR BIOTECHNOLOGY, INC.

(VIR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Vir Biotechnology : , GlaxoSmithKline Halts Enrollment in Phase 3 Trial of Experimental COVID-19 Drug

03/03/2021 | 10:57am EDT


© MT Newswires 2021
All news about VIR BIOTECHNOLOGY, INC.
06:18aVIR BIOTECHNOLOGY  : GlaxoSmithKline's SARS-CoV-2 Antibody Accepted for Rolling ..
MT
05:54aGSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VI..
GL
05/06VIR BIOTECHNOLOGY  : Earnings Flash (VIR) VIR BIOTECHNOLOGY Posts Q1 Revenue $2M
MT
05/06VIR BIOTECHNOLOGY  : Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Loss $-1...
MT
05/06VIR BIOTECHNOLOGY  : Posts Wider Q1 Loss on Lower Revenue, Cites Grant Timing
MT
05/06VIR BIOTECHNOLOGY, INC.  : Results of Operations and Financial Condition, Financ..
AQ
05/06VIR BIOTECHNOLOGY  : Provides Corporate Update and Reports First Quarter 2021 Fi..
AQ
05/06VIR BIOTECHNOLOGY  : Management's Discussion and Analysis of Financial Condition..
AQ
04/23VIR BIOTECHNOLOGY  : to Provide Corporate Update and Report First Quarter 2021 F..
AQ
04/22Vir Biotechnology to Provide Corporate Update and Report First Quarter 2021 F..
GL
More news
Financials (USD)
Sales 2021 397 M - -
Net income 2021 -234 M - -
Net cash 2021 364 M - -
P/E ratio 2021 -24,1x
Yield 2021 -
Capitalization 5 582 M 5 582 M -
EV / Sales 2021 13,1x
EV / Sales 2022 8,95x
Nbr of Employees 327
Free-Float 85,4%
Chart VIR BIOTECHNOLOGY, INC.
Duration : Period :
Vir Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIR BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 79,17 $
Last Close Price 42,97 $
Spread / Highest target 214%
Spread / Average Target 84,2%
Spread / Lowest Target -23,2%
EPS Revisions
Managers and Directors
NameTitle
George A. Scangos President, Chief Executive Officer & Director
Howard Horn CFO, Secretary & Principal Accounting Officer
Vicki L. Sato Non-Executive Chairman
Michael E. Kamarck Chief Technology Officer
Phil Pang Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VIR BIOTECHNOLOGY, INC.60.46%5 406
MODERNA, INC.53.63%64 284
LONZA GROUP AG1.05%46 978
IQVIA HOLDINGS INC.30.82%44 316
CELLTRION, INC.-25.77%30 699
SEAGEN INC.-20.36%24 694